Open AccessP009: Improved Overall Survival with First‐Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON‐1
Author(s) -
Hutchings Martin,
Ansell Stephen M.,
Connors Joseph M.,
Kim Won Seog,
Gallamini Andrea,
Ramchandren Radhakrishnan,
Friedberg Jonathan W.,
Advani Ranjana,
Evens Andrew M.,
Smolewski Piotr,
Savage Kerry J.,
Bartlett Nancy L.,
Eom HyeonSeok,
Abramson Jeremy S.,
Dong Cassie,
Campana Frank,
Fenton Keenan,
Puhlmann Markus,
Straus David J.,
Radford John
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000890604.66330.a0
Subject(s) - brentuximab vedotin , dacarbazine , abvd , medicine , hazard ratio , vinblastine , oncology , population , progression free survival , vincristine , lymphoma , confidence interval , surgery , chemotherapy , hodgkin lymphoma , cyclophosphamide , environmental health